Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy

Next Previous
Search
Trial Profile

Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Sleep disorders
  • Focus Therapeutic Use

Most Recent Events

  • 16 Dec 2015 Status changed from recruiting to completed as reported in ClinicalTrials.gov
  • 20 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 May 2015 as reported in ClinicalTrials.gov
  • 20 Feb 2015 Planned primary completion date changed from 1 Dec 2014 to 1 May 2015 as reported in ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top